{
  "Variants Include": [
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_004998.3:c.6056G>A",
          "cDNA Change": {
            "transcript": "NM_004998.3",
            "ref": "G",
            "alt": "A",
            "position": "6056"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "S",
            "position": "2019"
          },
          "Description in input context": "G2019S mutation"
        },
        {
          "HGVS": "NM_004998.3:c.6059T>C",
          "cDNA Change": {
            "transcript": "NM_004998.3",
            "ref": "T",
            "alt": "C",
            "position": "6059"
          },
          "Protein Change": {
            "ref": "I",
            "alt": "T",
            "position": "2020"
          },
          "Description in input context": "I2020T mutation"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson disease",
    "MONDO": "MONDO:0012975"
  },
  "Experiment Method": [
    {
      "Assay Method": "Binding assay",
      "Material used": {
        "Material Source": "N.D.",
        "Material Name": "N.D.",
        "Description": "N.D."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_004998.3:c.6056G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Altered ATP affinity",
          "Result Description": "G2019S shows reduced ATP affinity compared to wild-type."
        },
        {
          "Variant": "NM_004998.3:c.6059T>C",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Altered ATP affinity",
          "Result Description": "I2020T shows altered ATP affinity compared to wild-type."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "N.D."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type LRRK2 was used as a control."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Wild-type ATP affinity levels.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Significantly different ATP affinity compared to wild-type.",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "In vitro kinase activity assay",
      "Material used": {
        "Material Source": "N.D.",
        "Material Name": "N.D.",
        "Description": "N.D."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_004998.3:c.6056G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Reduced sensitivity to inhibitors",
          "Result Description": "G2019S exhibits reduced sensitivity to ATP-competitive inhibitors."
        },
        {
          "Variant": "NM_004998.3:c.6059T>C",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Increased resistance to inhibitors",
          "Result Description": "I2020T shows increased resistance to ATP-competitive inhibitors."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "N.D."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type LRRK2 was used as a control."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Wild-type inhibitor sensitivity levels.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Significant deviation in inhibitor sensitivity compared to wild-type.",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}